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Abstract
Background: Cholesteatoma are cyst-like structures lined with a matrix of differentiated squamous epithelium
overlying connective tissue. Although epithelium normally exhibits self-limited growth, cholesteatoma matrix erodes
mucosa and bone suggesting changes in matrix protein constituents that permit destructive behaviour. Differential
proteomic studies can measure and compare the cholesteatoma proteome to normal tissues, revealing protein
alterations that may propagate the destructive process.
Methods: Human cholesteatoma matrix, cholesteatoma-involved ossicles, and normal middle ear mucosa,
post-auricular skin, and non-involved ossicles were harvested. These tissues were subjected to multiplex peptide
labeling followed by liquid chromatography and tandem mass spectrometry analysis. Relative protein abundances
were compared and evaluated for ontologic function and putative involvement in cholesteatoma.
Results: Our methodology detected 10 764 peptides constituting 1662 unique proteins at 95 % confidence or greater.
Twenty-nine candidate proteins were identified in soft tissue analysis, with 29 additional proteins showing altered
abundances in bone samples. Ontologic functions and known relevance to cholesteatoma are discussed, with
several candidates highlighted for their roles in epithelial integrity, evasion of apoptosis, and immunologic function.
Conclusion: This study produced an extensive cholesteatoma proteome and identified 58 proteins with altered
abundances contributing to disease pathopathysiology. As well, potential biomarkers of residual disease were
highlighted. Further investigation into these proteins may provide useful options for novel therapeutics or
monitoring disease status.
Background
Cholesteatoma is a benign epidermal inclusion cyst that
develops within the temporal bone and exhibits locally
destructive behavior. Without treatment, cholesteatomas
can progressively expand and destroy middle ear and
temporal bone structures. This process can lead to sec-
ondary infections, which can result in complications
such as tympanic membrane perforation, chronic otor-
rhea, hearing loss, vestibular dysfunction, facial nerve
paresis, and intracranial extension [1]. Regardless of sur-
gical technique, cholesteatoma have propensity to recur
[2], requiring exteriorization of the middle ear through
canal wall down procedures or “second look” tympano-
mastoidectomy for surveillance of disease in intact canal
wall procedures.
Increased understanding of molecular changes in bone
through orthopedic and otitis media literature led to the-
ories of cholesteatoma-related bone destruction through
cellular resorption, mechanical compression, and second
mediator effects [2–7]. Bone erosion involved in the
progression of disease may be intrinsic to the choles-
teatoma—increased matrix growth factor and cytokine
expression, pressure effect of outward growth, and
host granulation enzymes. Extrinsic factors include
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bacterial superinfection, altered osteoclast activity in
response to invasion, and changes in bone architec-
ture and cell population [3, 7, 8]. Numerous targeted
molecular and genome wide studies on cholesteatoma
specimens support some of these hypotheses but fail
to appreciate the complex interplay between multiple
changes at the cellular level.
Differential proteomic analysis evaluates the active
protein constellation between normal and pathologic
states [9]. Initiated as two-dimensional gel electro-
phoresis (2DGE) with densitometry or visual evaluation,
modern proteomic analysis evolved to incorporate mass-
spectrometry in protein identification from individual
2DGE studies to current chromatographic separation and
tandem mass spectrometry techniques capable of analyz-
ing multiple tissue conditions simultaneously. Modern
mass spectrometry-based techniques have improved the
ability to recognize novel, replicable protein derangements
in various diseases and tissues by comparing disease to
normal states [10]. These changes can be detected among
proteins expressed at very low levels and several orders of
magnitude below that of the most abundant proteins.
Previous proteomic approaches to cholesteatoma
identified several proteins with altered presence in
comparison to post-auricular skin through 2DGE [11].
In this study, we employed a multiplex differential
mass spectrometry-based approach termed isotope-
tagged relative abundance quantification (iTRAQ) to
characterize simultaneously the cholesteatoma matrix
proteome in reference to native middle ear mucosa
and post-auricular skin as well as to evaluate the bone
proteome of ossicles involved by cholesteatoma com-
pared to normal ossicles. With this design we were
able to detect agents underlying the pathophysiologic
process and destructive behavior demonstrated by
cholesteatoma as well as identify and quantify poten-
tial biomarkers of disease.
Methods
Sample collection
This study received ethical approval from the University
of Calgary Conjoint Health Research Ethics Board (REB-
14-0883). Patient tissue samples were obtained during
primary tympanomastoidectomy from patients with ac-
quired cholesteatoma, whereby cholesteatoma matrix
was excised and cleaned of keratin debris; middle ear
mucosa was collected from uninvolved regions of the
mastoid cavity; post-auricular skin was taken as a 1 mm
wide strip of skin along the margin of the skin incision
with subcutaneous tissue removed by sharp dissection
under an operating microscope. Cholesteatoma-involved
ossicles were harvested during tympanomastoidectomy
from patients with evidence of ossicular destruction.
Control ossicles were obtained from patients undergoing
labyrinthectomy for vestibular schwannoma or ossicular
reconstruction for traumatic ossicular discontinuity. Tis-
sue samples were immediately placed on ice then stored
at −80 °C until sample processing.
Protein extraction
Samples were thawed on ice then washed three times in
4 °C phosphate-buffered saline containing complete prote-
ase inhibitor (Roche, Mississauga, ON). Sample processing
was performed by the following methods for either soft
tissue or bone, in an identical fashion for each tissue sam-
ple, with all buffers containing c0mplete protease inhibitor
(Roche, Mississauga, ON).
Soft tissue samples were pooled as mucosa, matrix, or
skin samples. Each pool was incubated at 4 °C for 16 h
in modified RIPA buffer with protease inhibitor. Samples
were then sonicated on ice for 7 s at 20 % power for 5 cy-
cles with 30 s cooling periods. The resultant lysates were
centrifuged for 60 min at 12 000 g at 4 °C in an Allegra
X-15R centrifuge (Beckman-Coulter, Mississauga, ON)
and the supernatant preserved. Equivalent total protein
concentrations from each pool were precipitated in
100 % chilled ethanol (Sigma, Oakville, ON) by incubat-
ing 24 h at −20 °C followed by 20 min centrifugation at
2500 g (4 °C). The pellet was preserved, washed once
with 80 % ethanol (v/v), centrifuged at 2500 g (4 °C),
decanted, and air dried for 5 min. The precipitated sam-
ples were stored at −80 °C until iTRAQ analysis.
Individual bone samples were incubated at room
temperature in 0.06 M hydrocholoric acid (HCl) for
16 h. The diluent (D1) was removed and the bone sam-
ples incubated in 1.2 M HCl at 4 °C for 16 h to decalcify
the bone. After decalcification, the diluent (D2) was re-
moved, and bone samples were pooled into two groups
(control ossicles or cholesteatoma-involved ossicles) then
washed with extraction buffer 1 (E1: 6 M guanidine-HCl
and 100 mM Tris–HCl with protease inhibitor). Buffer E1
was added to the pooled samples, which were sonicated
on ice for 7 s at 20 % power for 5 cycles with 30 s cooling
periods. Samples were incubated for 72 h at 4 °C then cen-
trifuged for 20 min at 12 000 g (4 °C). Supernatant E1 was
removed and stored at −80 °C. Samples were washed with
extraction buffer 1.5 (E1.5: 6 M guanidine-HCl, 100 mM
HEPES, 0.5 M Na4EDTA, protease inhibitor), then buf-
fer E1.5 was added to the pellet, agitated, and incubated
72 h at 4 °C. Samples were centrifuged for 20 min at 12
000 g at 4 °C, and supernatant E1.5 removed and stored
at −80 °C. Samples were washed with extraction buffer
2 (E2: 6 M HCl, 6 M guanidine-HCl, 100 mM 100 mM
Tris, protease inhibitor), then buffer E2 was added to
the pellet, fragmented, and incubated 20 h at 4 °C.
Samples D2, E1, E1.5, and E2 were combined in their
respective pooled samples and precipitated by the same
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method as the soft tissue samples and stored at −80 °C
until iTRAQ analysis.
iTRAQ reagent preparation
Two LC-MS/MS tracts were defined and run on separ-
ate days in order to minimize the impact of high abun-
dance proteins from each tissue type limiting the ability
to detect low abundance proteins: one for soft tissue and
one for bone samples. Soft tissue and bone lysates were
labelled with iTRAQ reagent according to the University
of Victoria Protein Centre protocols. 100 μg of total pro-
tein from each sample underwent acetone precipitation
followed by resuspension in iTRAQ buffer and trypsin
digestion. Each protein lysate was labeled with a distinct
isotopic iTRAQ reagent: control ossicles (113 Da),
cholesteatoma-involved ossicles (115 Da); cholesteatoma
matrix 1 (113 Da), cholesteatoma matrix 2 (114 Da),
mucosa (115 Da), post-auricular skin (116 Da). These
samples were combined and subjected to alkaline
(pH 10) reversed phase high performance liquid chro-
matography on an XBridge C18 BEH300 250 mm X
4.6 mm, 5 μm, 300A HPLC column (Waters, MA, USA),
with fractions collected every minute for 96 min.
LC-MS/MS analysis
Fractions were separated by on-line reversed phase
liquid chromatography using a Thermo Scientific EASY-
nanoLC II system with a reversed-phase pre-column
Magic C-18AQ (100 μm I.D., 2 cm length, and an in-
house prepared reversed-phase nano-analytical column
packed with Magic C-18AQ (75 μm I.D., 15 cm length,
5 μm, 100 Å; Michrom BioResources Inc, Auburn, CA).
The chromatography system was coupled on-line to an
LTQ Orbitrap Velos Pro mass spectrometer equipped
with a Nanospray Flex source (Thermo Fisher Scientific,
Bremen, Germany) and run over a 120 min gradient from
95 % solvent A (2 % Acetonitrile, 0.1 % Formic acid):5 %
solvent B (90 % Acetonitrile, 0.1 % Formic acid) to 100 %
solvent B. Mass spectrometry data were acquired with a
time of flight survey scan of mass range 400–1800 amu
where the most abundant ions exceeding 5000 counts and
charge state 2–4 selected for fragmentation.
Data acquisition and analysis
The resulting data were analyzed by Proteome Discoverer
1.4 software suite (Thermo Scientific) using stringency cri-
teria: s/n cut-off: 1.5; total intensity threshold: 0; mini-
mum peak count: 1; precursor mass: 350–5000 Da. The
peak lists were submitted to an in-house database search
using Mascot 2.4 (Matrix Science), and were searched
against the Uniprot-Swissprot database (May 30, 2015 up-
date; 540,261 sequences; 191,876,607 residues) assuming 2
or less missed trypsin cut sites as well as fixed methylthio
and variable oxidation and deamidation modifications.
Target false discovery rate was set a 0.01. All identified
proteins were assessed for gene ontology functions with
an additional function set for structural components and
those proteins with bone-related functions. Candidate
proteins were selected if their relative abundances were
greater than 1.5-fold (log2 scale) increased or decreased in
cholesteatoma matrix compared to either middle ear mu-
cosa or post-auricular skin for soft tissue analysis, or if
proteins in cholesteatoma-involved bone were greater
than 1.5-fold (log2 scale) increased or decreased relative to
control ossicles and found to have ontologic functions
corresponding to cellular metabolism, bone structure,
bone metabolism, or epithelial content.
Results
The soft tissue arm of our study included representative
samples from 12 cholesteatoma matrices, eight non-
diseased middle ear mucosa fragments, and nine post-
auricular skin samples. Healthy mucosa not involved
with cholesteatoma could not be identified in four pa-
tients and was not collected; three post-auricular skin
samples were suboptimal samples and not included.
iTRAQ analysis of the included samples detected 10 720
spectra representing 8372 unique peptides. Setting strin-
gency at 95 % probability of protein recognition and at
least two peptides per protein identified 1490 proteins
from 8315 of these peptides, corresponding to an aver-
age of 5.58 peptides per protein. The ontologic functions
of these proteins are displayed in Fig. 1a. Cellular metab-
olism, signal transduction, and DNA replication/tran-
scription/repair functions comprise more than 50 % of
the identified proteins.
With respect to the bone lysate analysis, which in-
cluded eight cholesteatoma-involved ossicles and eight
control ossicles, 3159 spectra and 2392 unique peptides
produced 480 proteins with at least two peptides and
95 % confidence of identification (4.96 peptides per pro-
tein). After subtracting protein clusters representing
homologous protein family members, 428 were recog-
nized with greater than 95 % confidence and further
scrutinized. Gene ontology functions for the identified
proteins are shown in Fig. 1b. The most common func-
tions identified were metabolism, signal transduction,
and bone structure, which accounted for 50 % of all pro-
teins; 10 % of proteins played a role in bone structure
and another 7 % in bone metabolism. In comparison to
the soft tissue analysis there were 256 common proteins,
indicating our study identified 1662 proteins from cho-
lesteatoma and involved middle ear structures.
Figures 2 and 3 display the proteins identified in the
soft tissue analysis with relative abundances of proteins
in mucosa and skin, respectively, compared to cholestea-
toma matrix. Proteins exceeding the relative abundance
threshold are highlighted in red and represent potential
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candidates in cholesteatoma pathophysiology or bio-
markers of disease. These 29 proteins are listed in Table 1
with their relative abundances in cholesteatoma matrix in
reference to both uninvolved mucosa and post-auricular
skin. Positive numbers indicate increased abundance in
cholesteatoma while negative values indicate a higher rela-
tive abundance in normal tissue. Similarly, Fig. 4 shows all
proteins identified in the bone analysis with potential can-
didates based on relative abundance alterations marked;
Table 2 contains the 33 proteins marked in Fig. 4 sorted
by relative abundance in cholesteatoma-involved ossi-
cles to uninvolved ossicles. Four proteins were present
in altered abundances in both the soft tissue and bone
tissue analyses: creatine kinase B-type (CKB), tenascin-
X (TNXB), serum amyloid P-component (APCS), and
keratin type 2 cytoskeletal 8 (KRT8).
Discussion
Our study used a mass spectrometry-based proteomic ap-
proach to evaluate the relative abundance changes between
proteins found within middle ear mucosa and post-
auricular skin relative to cholesteatoma matrix. A second
arm of the study investigated the protein changes occur-
ring in bone involved with cholesteatoma relative to
healthy ossicles. We identified a number of potential can-
didates in the molecular changes among the functional
components of the cholesteatoma matrix leading to un-
controlled growth and bony destruction.
Recognizing proteins with either increased or decreased
abundance in both skin and mucosa reflect deviations
from normal, particularly when they are functional rather
than primarily structural in nature. Proteins fitting this
description include members of the S100 family (A7, A8,
and A9) and SERPINB3. S100 proteins are elevated in
hyperproliferative skin disorders with primary roles in cell
cycle regulation and cell differentiation [12, 13]. S100A7
also functions in an antibacterial capacity through the
Toll-like receptor pathway in response to the bacterial
protein flagellin [14], which is found in P. aeruginosa and
E. coli, among other bacteria. SERPINB3 is a serine
Fig. 1 Ontologic functions of proteins identified in (a). Soft tissue analysis and (b). Bone analysis. General metabolic function and signal
transduction properties represent the most common ontologic functions in both tissue sets, but wide variation exists among the
remaining categories
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protease inhibitor associated with cellular atypia, evasion
of apoptosis, and cholesteatoma proliferation [15–17].
Our identification of SERPINB3 and the three S100 pro-
teins in cholesteatoma matrix agrees with existing litera-
ture noting increased levels in cholesteatoma relative to
post-auricular skin [11, 18], but it is a potentially novel
finding to find increased abundance relative to middle ear
mucosa. Though adult cholesteatoma is a disease of kera-
tinizing epithelium that likely originates from the lateral
surface of the tympanic membrane or external auditory
canal, its destructive properties occur primarily within the
middle ear; as such, finding difference between the
Fig. 2 Logarithm (base 2) plot of relative abundances of all proteins identified in cholesteatoma matrix in reference to control mucosa. Positive
values indicate greater protein content in cholesteatoma. The 15 proteins exceeding threshold abundances are indicated in red
Fig. 3 Logarithm (base 2) plot of relative abundances of all proteins identified in cholesteatoma matrix in reference to post-auricular skin. Positive
values indicate greater protein content in cholesteatoma. The 18 proteins exceeding threshold abundances are indicated in red
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cholesteatoma matrix that allows it to overgrow mucosa
and destroy neighbouring tissue may be more appreciable
by analyzing the mucosa of presumably unaffected middle
ear tissue.
A biomarker that is able to distinguish normal mucosa
from cholesteatoma could prove useful for intra-operative
tissue labeling or frozen section pathologic analysis, aiding
the surgeon in removing all diseased tissue. Therefore an-
other objective of this study was to recognize proteins that
may function as indicators of residual or recurrent disease.
As expected, the landscape of the cholesteatoma matrix
proteome resembles that of normal skin, with multiple
low-level abundance changes that likely reflect a complex
interplay between various proteins and gene expression
levels. The ideal candidate protein profile for this would
have increased relative abundance in cholesteatoma com-
pared to mucosa. Of the novel protein alterations we iden-
tified, some of the most intriguing changes involve
BLMH, TYMP, FLBP5, and FLG/FLG2. BLMH represents
a good candidate since it is located in superficial epidermis
and maintains epithelial integrity [19]. Increased BLMH
levels in cholesteatoma relative to mucosa, but unchanged
in skin, is logical given that it is found primarily in the
superficial and corneal layers of epidermis which are
largely deficient in the non-keratinizing middle ear epi-
thelium. This makes it an excellent potential biomarker
Table 1 Altered soft tissue protein abundances in cholesteatoma matrix relative to normal mucosa and post-auricular skin. Positive
values indicate a greater abundance of a protein in cholesteatoma than the reference tissue. Italicized relative abundances indicate
values below the detection threshold for one tissue but above detection threshold in the other. Study ID numbers correlate to
Figs. 2 and 3








Bleomycin hydrolase (842) BLMH 4 13.8 7.66 1.14
Protein S100-A9 (92) S100A9 5 55.3 4.66 3.83
Acyl-coenzyme A thioesterase 1 (1295) ACOT1 2 5.7 4.62 −1.26
Filaggrin (294) FLG 10 3.7 4.50 2.14
FA binding protein, epidermal (319) FABP5 7 65.2 4.32 2.55
Filaggrin-2 (621) FLG2 3 1.0 4.15 1.35
Protein S100-A7 (138) S100A7 7 54.5 3.81 3.25
Creatine kinase B-type (944) CKB 2 7.9 3.74 1.47
Protein S100-A8 (162) S100A8 5 64.5 3.50 3.80
Thymidine phosphorylase (150) TYMP 10 35.1 3.32 1.52
Serine protease inhibitor B3 (69) SERPINB3 22 50.3 3.30 3.12
Myelin protein P0 (523) MPZ 6 25.0 2.92 1.06
Desmocollin-3 (989) DSC3 3 4.2 2.07 −3.42
Ferritin light chain (965) FTL 3 19.4 1.42 3.13
Fatty acid desaturase 2 (1301) FADS2 2 3.6 1.32 −5.34
Hydroxymethylglutaryl-CoA synthase, cytoplasmic (705) HMGCS1 2 6.0 1.30 −3.32
Fatty acid synthase (37) FASN 38 23.7 1.29 −3.65
Collagen alpha-1(III) chain (754) COL3A1 3 2.7 1.26 −5.15
Collagen alpha-6(VI) chain (260) COL6A6 10 7.0 1.18 −3.95
Integrin alpha-M (909) ITGAM 4 3.9 1.16 3.28
Keratin, type II cytoskeletal 79 (359) KRT79 15 27.7 −1.03 −5.48
Tenascin-X (111) TNXB 23 8.2 −1.18 −4.05
Serum amyloid P-component (269) APCS 5 23.3 −1.23 −3.27
Tryptase alpha/beta-1 (382) TPSAB1 4 14.5 −1.65 −4.23
Collagen alpha-2(I) chain (151) COL1A2 7 54.5 −1.86 −7.48
Mimecan/osteoglycin (126) OGN 7 24.8 −1.89 −5.49
Keratin type 2 cytoskeletal 8 (471) KRT8 13 21.7 −2.85 −1.55
BPI fold containing family member B (865) BPIFB1 3 8.5 −3.06 1.68
Fibrillin-1 (70) FBN1 27 11.3 −3.08 −1.23
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since presence in the middle ear following cholestea-
toma excision may represent residual disease. Likewise,
FLG is long recognized as elevated in cholesteatoma by
histopathologic studies relative to post-auricular skin
[20, 21], and we note considerably greater degree of ele-
vation in cholesteatoma compared to mucosa with
similar change noted in FLG2, which is co-expressed
with FLG during keratinocyte differentiation [22]. Pre-
vious data suggests an interaction between FLG and
involucrin (IVL), a protein that creates a protective en-
velope around corneocytes, and increased IVL in cho-
lesteatoma [21, 23]; we identified increased IVL in
cholesteatoma matrix, but not at levels meeting detec-
tion threshold (1.97-fold increase).
TYMP abundance was elevated in cholesteatoma 3.25-
fold in our study compared to mucosa, though less so
compared to post-auricular skin. TYMP is an angiogenesis
factor involved in avoiding hypoxia-induced apoptosis,
though most research focuses on malignant disease [24].
The role of hypoxia in cholesteatoma is poorly understood
and thought to stimulate matrix metalloprotease release
and subsequent perimatrix degeneration [25]. Elevated
TYMP may contribute to the independent growth capabil-
ity of cholesteatoma particularly when oxygen require-
ments exceed that available from direct diffusion in
aerated portions of the middle ear. In addition to oxygen
supply, energy demand is another hurdle cholesteatoma
must overcome to continue growth and local destructive
potential. Fatty acid metabolism is gaining attention in
cholesteatoma pathophysiology as an available energy
source to propagate self-sufficient growth [25]. We found
epidermal fatty acid binding protein (FABP5) is highly
overabundant in cholesteatoma compared to normal mu-
cosa (4.3-fold), with a lesser increase compared to skin.
Initially identified in psoriasis, FABP5 is unique to kerati-
nocytes, is a key factor in keratinocyte differentiation, and
interacts with other proteins found at altered abundances
in our study [26]. Of note, increased FABP5 stimulates in-
creased IVL and is stabilized by S100A7 [27, 28]. FABP5
also appears to have a role in inflammatory change and
tissue injury involving keratinocytes [29].
Other notable observations are the reduction of several
structural proteins in cholesteatoma compared to post-
auricular skin. These proteins provide insight into the mo-
lecular changes occurring that cause the well-recognized
fragility of matrix intra-operatively. Desmocollin-3 (DSC3)
likely contributes to this friability, as loss of function is
found in skin fragility disorders [30], which matches the
abundance profile we observed with decreased levels
(3.42-fold) in cholesteatoma compared to skin, but above
that seen in mucosa. Intercellular tight junction loss in
cholesteatoma compared to normal skin has been shown
by electrical impedence studies, agreeing with the im-
paired intercellular connections we found [31]. As shown
in Table 1, a large proportion of the proteins reduced in
cholesteatoma relative to skin are structural components.
With respect to the bone proteome of cholesteatoma-
involved ossicles, the extensive number of changes
Fig. 4 Logarithm (base 2) plot of relative abundances of all proteins identified in cholesteatoma-involved ossicles in reference to control ossicles.
Positive values indicate greater protein content in cholesteatoma-involved bone. The 34 proteins exceeding threshold abundances and meeting
inclusion criteria are highlighted in red
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mirrors the complexity of bone as an organ. Many of
these changes relate to increased metabolic function,
protein degradation, and inflammatory response and less
so with structural components. A number of the proteins
are constituents of the endoplasmic reticulum, which is
abundant in osteoblasts for their synthetic function.
Among the proteins with functional ontologic duties,
Tenascin-X (TNXB), Serine protease inhibitor H1
(SERPINH1), and Neutrophil elastase (ELANE), are
known factors in bone remodeling. TNXB, decreased in
cholesteatoma-involved bone relative to normal ossicles
and one of the proteins common to bone and soft tissue
analyses, stabilizes extracellular matrix and collagen fibril
formation; reduced TNXB is associated with abnormal
collagen and elastin deposition and extracellular matur-
ation [32–34]. Whether altered TNXB levels in our study
Table 2 Altered abundances of proteins found in the cholesteatoma matrix proteome relative to healthy ossicles. Positive values
indicate increased protein abundance in cholesteatoma. Study ID numbers correlate to Fig. 4








Isocitrate dehydrogenase 2 (199) IDH2 3 4.6 11.02
Creatine kinase B type (187) CKB 3 9.7 7.81
Thioredoxin domain-co8ntaining protein 5 (290) TXNDC5 3 12.0 6.76
Cytoskeleton-associated protein 4 (379) CKAP4 2 4.8 4.64
Protein disulfide-isomerase A6 (166) PDIA6 5 15.2 4.45
Ribosome binding protein 1 (251) RRBP1 3 2.4 4.19
Peptidyl-prolyl cis-trans isomerase (368) FKBP10 2 4.5 4.06
ATP synthase subunit α, mitochondrial (97) ATP5A1 9 21.2 3.92
Superoxide dismutase, mitochondrial (377) SOD2 2 17.2 3.92
60S ribosome L14 (298) RPL14 2 10.7 3.73
Stress-10 protein, mitochondrial (290) HSPA9 3 12.0 3.73
Guanine nucleotide binding protein subunit β-2 (283) GNB2L1 4 18.3 3.63
Malate dehydrogenase 2 (165) MDH2 6 25.4 3.62
Serine protease inhibitor H1 (248) SERPINH1 4 14.6 3.50
Dolichyl-diphosphooligosaccharide–protein glycosyltransferase (284) DDOST 3 7.7 3.48
Elongation factor Tu (253) TUFM 3 10.6 3.45
ATP synthase subunit β, mitochondrial (105) ATP5B 6 14.6 3.41
ADP/ATP translocase 2 (134) SLC25A5 8 24.8 3.37
Neutrophil elastase (269) ELANE 2 6.7 3.31
Cathepsin G (113) CTSG 5 22.4 3.29
Staphylococcal nuclease domain-containing protein 1 (386) SND1 2 2.5 3.28
Very long chain specific acyl-CoA dehydrogenase (354) ACADVL 2 3.5 3.26
Coatamer subunit gamma-1 (323) COPG1 2 2.6 3.13
Prohibitin-2 (358) PHB2 2 9.7 2.99
Lamin-B1 (396) LMNB1 2 3.4 2.98
Valine—tRNA ligase (299) VARS 2 2.1 2.97
Aspartate aminotransferase, mitochondrial (344) GOT2 2 5.1 2.91
3-Hydroxyacyl-coA dehydrogenase type 2 (267) HSD17B10 2 12.3 2.89
Membrane primary amine oxidase (225) AOC3 4 3.7 −3.04
Keratin type II cytoskeletal 8 (337) KRT8 3 6.2 −3.59
Collagen VIII, α-1 chain (208) COL8A 3 5.0 −3.66
Cochlin (17) COCH 11 20.4 −4.00
Keratin type II cytoskeletal 7 (164) KRT7 6 13.4 −4.70
Tenascin-X (336) TNXB 3 0.8 −4.84
Serum amyloid P-component (93) APCS 5 21.5 −5.96
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reflect a pathologic or reactive change to cholesteatoma
remains to be seen. SERPINH1 is a serine protease inhibi-
tor molecular chaperone with critical function in endo-
chondral bone and cartilage formation [35]. Elevated
SERPINH1 in cholesteatoma-involved ossicles suggests ei-
ther increased bone remodeling or repair of the affected
bones. This is also likely the scenario for our observation
of increased ELANE in cholesteatoma-involved bone.
Involved in innate cellular immune processes, ELANE
also functions in Collagen VI breakdown and matrix
metalloprotease activation [36]. As noted in the soft tissue
analysis, proteins present at increased abundances in
cholesteatoma-involved bone may also represent markers
of residual disease. Cytoskeleton-associated protein 4
(CKAP4) primarily functions in skin development and
maintenance [37], implying its presence in cholesteatoma-
involved bone correlates with presence of invasive disease.
Limitations of our study center on the use of a large-
scale proteomic approach to the identification of these
altered protein abundances. We found several abun-
dance differences between cholesteatoma matrix and
skin compared to the difference between matrix and
mucosa. This is challenging to explain but may represent
an alteration in protein composition in epidermis as
cholesteatoma matures. One possible reason for this is
that the local environment in the middle ear is different
from that of the exposed post-auricular region. Alterna-
tively, dermal elements could be underrepresented or
absent in cholesteatoma while they would not be present
in mucosa since there is no appreciable submucosa in
the middle ear. Yet another consideration is the inability
to measure proteins present in very low abundances,
since the peptide fragments from these proteins fail to
reach detection thresholds due to the presence of peptides
from highly expressed proteins. This remains a challenge
to all proteomic studies, although mass spectrometry-
based techniques have a wider dynamic range than trad-
itional 2DGE [10, 38].
Additional limitations specific to biomarker discovery
studies warrant mention. Identification of disease bio-
markers represents a chief objective of proteomics, though
to date it as been difficult to carry putative biomarkers
through to clinical practice, mainly due to variation be-
tween populations and study validity [39]. Discovery phase
studies generally use samples containing well-defined and
discrete disease states that do not necessarily reflect early,
subclinical disease, which would be the ideal target for dis-
ease prevention. Similarly, patients with advanced disease
often present in a condition that does not match the dis-
ease state used to identify the biomarker. Current candi-
dates discovered with large scale proteomic approaches
currently under inquiry for roles in clinical diagnostics and
disease management include proteins altered in COPD
[40], lung cancer [40, 41], gastrointestinal malignancy [42],
transplant rejection [43], metabolic diseases [44]. Nonethe-
less, at present no single protein biomarker discovered
through proteomics demonstrates sufficient accuracy to
predict disease in a subclinical state [45]. Multiplex ap-
proaches to biomarker development present promise to
increase understanding of diseases by simultaneously test-
ing multiple proteins and observing abundance changes in
concert, and to provide biomarker panels with increased
accuracy [45].
Conclusions
In conclusion, we used a large-scale, two armed prote-
omic approach to identify and quantify the changes in
protein abundance levels in cholesteatoma matrix rela-
tive to normal middle ear mucosa and post-auricular
skin, as well as in ossicles invaded by cholesteatoma
compared to normal ossicles. Given the quantity of pro-
teins involved in epithelial integrity and metabolism, our
results provide several avenues for future research into
cholesteatoma pathophysiology. Moreover, our inclusion
of middle ear mucosa noted novel protein increases in
matrix compared to post-auricular skin. One of the excit-
ing findings in our study is the large number of potential
biomarkers to use for evaluating residual or recurrent dis-
ease, in particular BLMH, TYMP, FLBP5, FLG/FLG2, and
CKAP4. Our results describe several accessible proteins
that could be used, if future validation demonstrates they
are present in altered abundances in cholesteatoma com-
pared to nascent mucosa, as potential therapeutic or diag-
nostic targets with the aim of reducing recurrent or
residual disease and the need for second look tympano-
mastoidectomy. The greatest challenge with cholesteatoma
surgery is eradicating disease without compromising func-
tion. Ideally, future cholesteatoma surgery could incorpor-
ate intraoperative or postoperative histopathologic margin
evaluation using these biomarkers to reduce residual dis-
ease and determine timing of second look surgery.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
DRR developed the study protocol, prepared ethics approval, performed
molecular analysis, analyzed data, and drafted the manuscript. PSP assisted
with study design, data analysis, sample collection, and manuscript
development. JKC contributed to study design, ethics application
preparation, sample collection, data analysis, and manuscript preparation. All
authors read and approved the final manuscript.
Acknowledgments
The authors thank the University of Calgary Office of Surgical Research
(Calgary Surgical Research Development Fund) and the Campbell MacLaurin
Foundation for Hearing Research for providing funding to support this study.
We also thank Dr. Karl Riabowol for providing laboratory facilities to prepare
tissue lysates, Dr. Lorne Clarke for technical advice on bone proteome
isolation, and the University of Victoria Genome BC Protein Centre for their
expertise in proteomic analysis.
Randall et al. Journal of Otolaryngology - Head and Neck Surgery  (2015) 44:50 Page 9 of 10
Funding
University of Calgary Surgical Research Development Fund, Campbell
McLaurin Foundation for Hearing Research.
Received: 3 June 2015 Accepted: 10 November 2015
References
1. Prasad SC, Shin SH, Russo A, Di Trapani G, Sanna M. Current trends in
the management of the complications of chronic otitis media with
cholesteatoma. Curr Opin Otolaryngol Head Neck Surg. 2013;21(5):446–54.
2. Mishiro Y, Sakagami M, Kitahara T, Kondoh K, Okumura S. The investigation
of the recurrence rate of cholesteatoma using Kaplan-Meier survival analysis.
Otol Neurotol. 2008;29(6):803–6.
3. Jung JY, Chole RA. Bone resorption in chronic otitis media: the role of the
osteoclast. ORL J Otorhinolaryngol Relat Spec. 2002;64:95–107.
4. Olszewska E, Wagner M, Bernal-Sprekelsen M, Ebmeyer J, Dazert S,
Hildmann H, et al. Etiopathogenesis of cholesteatoma. Eur Arch
Otorhinolaryngol. 2004;261(1):6–24.
5. Morales SD, Penido N de O, da Silva NID, Stavale JN, Guilherme A, Fukuda Y.
Matrix metalloproteinase 2: an important genetic marker for cholesteatomas.
Braz J Otorhinolaryngol. 2007;73:51–7.
6. Nason R, Jung JY, Chole RA. Lipopolysaccharide-induced osteoclastogenesis
from mononuclear precursors: a mechanism for osteolysis in chronic otitis.
J Assoc Res Otolaryngol. 2009;10:151–60.
7. Louw L. Acquired cholesteatoma pathogenesis: stepwise explanations.
J Laryngol Otol. 2010;124(6):587–93.
8. Kuo CL. Etiopathogenesis of acquired cholesteatoma: prominent
theories and recent advances in biomolecular research. Laryngoscope.
2015;125(1):234–40.
9. Aggarwal K, Choe LH, Lee KH. Shotgun proteomics using the iTRAQ isobaric
tags. Brief Funct Genomic Proteomic. 2006;5(2):112–20.
10. Feist P, Hummon AB. Proteomic challenges: sample preparation techniques
for microgram-quantity protein analysis from biological samples. Int J Mol
Sci. 2015;16(2):3537–63.
11. Kim JL, Jung HH. Proteomic analysis of cholesteatoma. Acta Otolaryngol.
2004;124(7):783–8.
12. Lee Y, Jang S, Min JK, Lee K, Sohn KC, Lim JS, et al. S100A8 and S100A9 are
messengers in the crosstalk between epidermis and dermis modulating a psoriatic
milieu in human skin. Biochem Biophys Res Commun. 2012;423(4):647–53.
13. Hattori F, Kiatsurayanon C, Okumura K, Ogawa H, Ikeda S, Okamoto K, et al.
The antimicrobial protein S100A7/psoriasin enhances the expression of
keratinocyte differentiation markers and strengthens the skin's tight junction
barrier. Br J Dermatol. 2014;171(4):742–53.
14. Abtin A, Eckhart L, Mildner M, Gruber F, Schröder JM, Tschachler E. Flagellin is the
principal inducer of the antimicrobial peptide S100A7c (psoriasin) in human
epidermal keratinocytes exposed to Escherichia coli. FASEB J. 2008;22(7):2168–76.
15. Suminami Y, Kishi F, Sekiguchi K, Kato H. Squamous cell carcinoma antigen
is a new member of the serine protease inhibitors. Biochem Biophys Res
Commun. 1991;181(1):51–8.
16. Vidalino L, Doria A, Quarta S, Zen M, Gatta A, Pontisso P. SERPINB3,
apoptosis and autoimmunity. Autoimmun Rev. 2009;9(2):108–12.
17. Quarta S, Vidalino L, Turato C, Ruvoletto M, Calabrese F, Valente M, et al.
SERPINB3 induces epithelial-mesenchymal transition. J Pathol. 2010;221(3):343–56.
18. Ho KY, Huang HH, Hung KF, Chen JC, Chai CY, Chen WT, et al.
Cholesteatoma growth and proliferation: relevance with serpin B3.
Laryngoscope. 2012;122(12):2818–23.
19. Schwartz DR, Homanics GE, Hoyt DG, Klein E, Abernethy J, Lazo JS. The neutral
cysteine protease bleomycin hydrolase is essential for epidermal integrity and
bleomycin resistance. Proc Natl Acad Sci USA. 1999;96(8):4680–5.
20. Stammberger M, Bujía J, Kastenbauer E. Alteration of epidermal
differentiation in middle ear cholesteatoma. Am J Otol. 1995;16(4):527–31.
21. Min HJ, Park CW, Jeong JH, Cho SH, Kim KR, SH L. Comparative analysis of
the expression of involucrin, filaggrin and cytokeratin 4, 10, 16 in
cholesteatoma. Korean J Audiol. 2012;16(3):124–9.
22. Makino T, Mizawa M, Yamakoshi T, Takaishi M, Shimizu T. Expression of
filaggrin-2 protein in the epidermis of human skin diseases: a comparative
analysis with filaggrin. Biochem Biophys Res Commun. 2014;449(1):100–6.
23. Huisman MA, De Heer E, Grote JJ. Survival signaling and terminal differentiation
in cholesteatoma epithelium. Acta Otolaryngol. 2007;127(4):424–9.
24. Ikeda R, Tajitsu Y, Iwashita K, Che XF, Yoshida K, Ushiyama M, et al.
Thymidine phosphorylase inhibits the expression of proapoptotic protein
BNIP3. Biochem Biophys Res Commun. 2008;370(2):220–4.
25. Louw L. Acquired cholesteatoma: summary of the cascade of molecular
events. J Laryngol Otol. 2013;127(6):542–9.
26. Dallaglio K, Marconi A, Truzzi F, Lotti R, Palazzo E, Petrachi T, et al. E-FABP induces
differentiation in normal human keratinocytes and modulates the differentiation
process in psoriatic keratinocytes in vitro. Exp Dermatol. 2013;22(4):255–61.
27. Hagens G, Roulin K, Hotz R, Saurat JH, Hellman U, Siegenthaler G. Probable
interaction between S100A7 and E-FABP in the cytosol of human
keratinocytes from psoriatic scales. Mol Cell Biochem. 1999;192(1–2):123–8.
28. Ruse M, Broome AM, Eckert RL. S100A7 (psoriasin) interacts with epidermal
fatty acid binding protein and localizes in focal adhesion-like structures in
cultured keratinocytes. J Invest Dermatol. 2003;121(1):132–41.
29. Kusakari Y, Ogawa E, Owada Y, Kitanaka N, Watanabe H, Kimura M, et al.
Decreased keratinocyte motility in skin wound on mice lacking the epidermal
fatty acid binding protein gene. Mol Cell Biochem. 2006;284(1–2):183–8.
30. Hartlieb E, Kempf B, Partilla M, Vigh B, Spindler V, Waschke J. Desmoglein 2
is less important than desmoglein 3 for keratinocyte cohesion. PLoS One.
2013;8(1), e53739.
31. Koizumi H, Suzuki H, Ohbuchi T, Kitamura T, Hashida K, Nakamura M.
Increased permeability of the epithelium of middle ear cholesteatoma.
Clin Otolaryngol. 2015;40(2):106–14.
32. Zweers MC, van Vlijmen-Willems IM, van Kuppevelt TH, Mecham RP, Steijlen
PM, Bristow J, et al. Deficiency of tenascin-X causes abnormalities in dermal
elastic fiber morphology. J Invest Dermatol. 2004;122(4):885–91.
33. Egging D, van den Berkmortel F, Taylor G, Bristow J, Schalkwijk J.
Interactions of human tenascin-X domains with dermal extracellular matrix
molecules. Arch Dermatol Res. 2007;298(8):389–96.
34. Egging D, van Vlijmen-Willems I, van Tongeren T, Schalkwijk J, Peeters A.
Wound healing in tenascin-X deficient mice suggests that tenascin-X is
involved in matrix maturation rather than matrix deposition. Connect Tissue
Res. 2007;48(2):93–8.
35. Masago Y, Hosoya A, Kawasaki K, Kawano S, Nasu A, Toguchida J, et al. The
molecular chaperone Hsp47 is essential for cartilage and endochondral
bone formation. J Cell Sci. 2012;125(Pt 5):1118–28.
36. Kielty CM, Lees M, Shuttleworth CA, Woolley D. Catabolism of intact type VI
collagen microfibrils: susceptibility to degradation by serine proteinases.
Biochem Biophys Res Commun. 1993;191(3):1230–6.
37. Koster MI. p63 in skin development and ectodermal dysplasias. J Invest Dermatol.
2010;130(10):2352–8.
38. Choe LH, Aggarwal K, Franck Z, Lee KH. A comparison of the consistency of
proteome quantitation using two-dimensional electrophoresis and shotgun
isobaric tagging in Escherichia coli cells. Electrophoresis. 2005;26(12):2437–49.
39. Lin JL, Bonnichsen MH, Nogeh EU, Raftery MJ, Thomas PS. Proteomics in
detection and monitoring of asthma and smoking-related lung diseases.
Expert Rev Proteomics. 2010;7(3):361–72.
40. Ohlmeier S, Vuolanto M, Toljamo T, Vuopala K, Salmenkivi K, Myllärniemi M, et
al. Proteomics of human lung tissue identifies surfactant protein A as a marker
of chronic obstructive pulmonary disease. J Proteome Res. 2008;7(12):5125–32.
41. Bajtarevic A, Ager C, Pienz M, Klieber M, Schwarz K, Ligor M, et al.
Noninvasive detection of lung cancer by analysis of exhaled breath. BMC
Cancer. 2009;9:348.
42. Kuramitsu Y, Nakamura K. Proteomic analysis of cancer tissues: shedding light
on carcinogenesis and possible biomarkers. Proteomics. 2006;6(20):5650–61.
43. Cohen Freue GV, Meredith A, Smith D, Bergman A, Sasaki M, Lam KK, et al.
Biomarkers in Transplantation and the NCE CECR Prevention of Organ
Failure Centre of Excellence Teams. Computational biomarker pipeline from
discovery to clinical implementation: plasma proteomic biomarkers for
cardiac transplantation. PLoS Comput Biol. 2013;9(4), e1002963.
44. Randall DR, Sinclair GB, Colobong KE, Hetty E, Clarke LA. Heparin cofactor
II-thrombin complex in MPS I: a biomarker of MPS disease. Mol Genet
Metab. 2006;88(3):235–43.
45. Schiess R, Wollscheid B, Aebersold R. Targeted proteomic strategy for
clinical biomarker discovery. Mol Oncol. 2009;3(1):33–44.
Randall et al. Journal of Otolaryngology - Head and Neck Surgery  (2015) 44:50 Page 10 of 10
